US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug Sunlenca (lenacapavir). The drug is approved for use in combination with antiretroviral drugs for adult patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection who are unable to achieve virological suppression with their current treatment plan.
Lenacapavir: A Long-Acting HIV Capsid Inhibitor with Unique Dosing
Lenacapavir, a long-acting HIV capsid inhibitor, is already registered in the US, European Union, Japan, and other regions. It is distinguished as the only AIDS treatment drug in the world that requires administration only twice a year, with tablets needing to be taken orally just once a week. This innovative dosing regimen has the potential to significantly improve treatment adherence and quality of life for patients living with HIV-1.
Expanding Treatment Options for HIV-1 Patients in China
The approval of Sunlenca (lenacapavir) by the NMPA marks a significant expansion in treatment options for adult patients in China who are battling multidrug-resistant HIV-1 infection. Gilead Sciences continues to lead in the development of innovative HIV treatments, addressing the complex needs of patients with limited treatment options.-Fineline Info & Tech
